[Edaily Reporter Kwon Oh Seok ] ABL Bio Inc.(298380)announced on the 9th that it had received approval for an amendment to the Investigational New Drug (IND) application for its bispecific antibody immunotherapy ABL503. The clinical trial was approved by the U.S. Food and Drug Administration (FDA), and the target indication is advanced or metastatic solid tumors.
Disclosure Plus
ABL Bio Inc. Receives Approval to Amend IND for Phase 1 Trial of Bispecific Antibody Immunotherapy
Kwon Oh Seok
2026-07-09 15:18:25
Economy
Corporation
IT·Science
Economy
TONGYANG LIFE INSURANCE to Become a Wholly-Owned Subsidiary of WOORIRO CO., LTD… Delisting Procedures to Begin at the End of This Month
TONGYANG LIFE INSURANCE is set to undergo delisting procedures following its acquisition as a wholly-owned subsidiary of WooriFinancialGroup.
A view of TONGYANG LIFE INSURANCE’s headquarters in Jon…
Corporation
COSMAX, INC. Reports 'Record-High' Second-Quarter Earnings… U.S. Subsidiary Posts First Profit Since Inception
Global cosmetics Original Design Manufacturer (ODM) company COSMAX, INC.(192820)posted its best-ever quarterly results in the second quarter of this year. With domestic and overseas subsidiaries showi…
IT·Science
SOCAR Posts Operating Profit for 8 Consecutive Quarters… Car-Sharing and Parking Businesses Grow in Tandem
SOCAR(403550)has posted an operating profit for the eighth consecutive quarter, driven by growth in its core car-sharing business and the expansion of its parking platform. Investments in user-centric…
